HS#WUXI RC2608A

Morgan Stanley Raises Target Price for Wuxi Biologics to 50 HKD

WuXi Biologics Anticipates 16.7% Revenue Growth to 21.79 Billion Yuan in 2025; Gross Margin to Increase by 5 Percentage Points to 46%

WuXi Biologics Reports Preliminary Full Year Net Profit Exceeding Expectations

WuXi Biologics Anticipates Revenue and Gross Margin Growth in 2025

WuXi Biologics Signs Innovative Tri-Specific TCE Development Agreement with Vertex Pharmaceuticals

WuXi Biologics Signs License and Research Agreement for Tri-specific T-cell Engager with Vertex Pharmaceuticals

WuXi Biologics and Sunovian Announce Strategic Collaboration on SND006 Process Development and Manufacturing

Morgan Stanley Reduced Stake in Wuxi Biologics (Cayman)

CLSA Report: Wuxi Biologics Outperforms Peers

WuXi Biologics and WuXi ChemPartner to Acquire at Least 60% of Tonox

CICC Maintains Buy Rating on Wuxi Biologics (Cayman)

Multiple HK-listed Companies Announce Major Updates

Major Wuxi Biologics Shareholder Sells Existing Shares

Wu Xiaosheng, CEO of WuXi Biologics, Speaks at JPM Healthcare Conference

Citi Group Launches Voluntary Cash Offer to Acquire eXiao Technology Cayman

WuXi Biologics and Zai Lab Sign TCE Research Collaboration Agreement

Morgan Stanley Maintains Wuxi Biologics 'Neutral' Rating, Raises Target Price

Daiwa Raises Target Price for Wuxi Biologics to HKD 42

WuXi Biologics' Wuxi Factories Obtain GMP Certification and Provide Ophthalmic Biologic Production

WuXi Biologics Briefs on 2026 Business Growth Prospects at Annual Healthcare Conference

BOER POWER

WAI CHUN GROUP

HUAYUEXPRESSWAY

ASIA ENERGY LOG

KNOWLEDGE ATLAS

HING LEE (HK)

JH EDUCATION

TBKS HLDGS

SIMPLICITY HLDG

159837

159316

588860

159859

513120

512290

159992

159615

159102

02269

516500

520880

588250

520690

159849

Bank of America Securities released a research report, indicating that WUXI BIO is expected to see revenue growth of 16.7% to 21.8 billion yuan in 2025, with gross margin improving to 46%. Net profit is expected to be 5.7 billion, representing a year-on-year growth of 45.3%. The firm raised its target price from HKD 41.8 to HKD 47, maintaining a "Neutral" rating

AASTOCKS

E Fund CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ICBCCS SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI 300 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

WUXI BIO

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

China Merchants CSI Biotechnology Theme ETF

"Big Banks" Bank of America Securities: WUXI BIO's earnings surprise is stable, raising target price to 47 yuan

00020

02359

09899

03690

09961

MPNGY

603259

The Hong Kong stock market was under pressure in the morning session, with the Hang Seng Index down 242 points, closing at 27,023 points. The National Index fell by 89 points, and the Hang Seng Tech Index dropped by 92 points. Technology stocks generally declined, with Trip.com, Meituan, and NetEase experiencing significant losses. SenseTime rose 5.2% against the trend. Market expectations for a Federal Reserve rate cut have cooled, leading to a slight decline of 66 points in the Dow Jones Industrial Average

SENSETIME-W

WUXI APPTEC

NETEASE MUSIC

MEITUAN

TRIP.COM-S

Meituan

WuXi AppTec

NTES-S

NetEase

"Hong Kong Stocks" Hang Seng Index fell 242 points in the half-day, with technology investment stocks leading the decline, while domestic property and WuXi AppTec stocks performed well

02268

Nomura's research report indicates that WUXI BIO is expected to see a revenue increase of 16.7% to RMB 21.8 billion in 2025, exceeding market expectations. The gross margin is expected to improve to 46%, and net profit is projected to grow by 45.3% to RMB 5.7 billion. The firm has raised the target price to HKD 50.54 and maintains a "Buy" rating, believing that its subsidiary WUXI XDC will make a significant contribution to revenue growth

WUXI XDC

Nomura raises WUXI BIO's target price to 50.54 yuan, with preliminary annual performance exceeding expectations

01876

The Hong Kong stock market showed a weak performance in the early session, with the Hang Seng Index opening down 55 points at 27,210 points. Technology stocks generally declined, with MEITUAN opening down 2.5%, Alibaba down 1.4%, and Tencent down 2%. NetEase's net profit fell short of expectations, leading to a 1.4% drop in its stock price. BUD APAC's net profit fell by 32.6% last year, resulting in a 2.1% decline in its stock price. In contrast, WUXI BIO opened up 2.7%, making it the best-performing blue-chip stock

BUD APAC

"Hong Kong Stocks" The Hang Seng Index opened 55 points lower, Netease and Bud APAC declined, WUXI BIO rose

516930

588130

WXXWY

WuXi XDC Cayman Inc. has launched a voluntary conditional cash offer to acquire all remaining shares of BioDlink not already owned by WuXi XDC and its concert parties. The offer includes the cancellation of all outstanding share options of BioDlink. This initiative follows a joint announcement by WuXi XDC, WuXi Biologics, and BioDlink to consolidate ownership in BioDlink.

Reuters

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

WuXi Biologics

WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink

China stocks remained steady on Wednesday, with metal-linked stocks offsetting losses in consumer and AI sectors. The CSI300 Index fell 0.2%, while the Shanghai Composite rose 0.2%. The CSI Non-ferrous Metal Industry Index surged 3.2%. The central bank plans to enhance financial support to boost domestic demand amid weak consumption. Consumer staples dipped 0.2%, and AI shares dropped 1.7%. UBS predicts a release of excess savings by 2026, potentially boosting market investments. Policymakers aim for sustainable growth while managing market pace. WuXi Biologics shares rose 4% on strong earnings.

China stocks steady as metals rally counters consumer, AI losses

HSAI

The Hang Seng Index rose 82 points (0.3%) to close at 27,266, marking its third consecutive gain, driven by broad sector advances and positive sentiment from China's central bank's commitment to boost domestic demand. However, concerns over industrial overcapacity and weak consumption led to a trimming of morning gains. Notable stock movements included Hesai Group (+6.4%), SenseTime (+2.9%), and WuXi Biologics (+3.6%), while SMIC fell 2.7% amid industry concerns.

- The Hang Seng Index rose 82 points, or 0.3%, to close at 27,266, continuing its upward trend amid broad sector gains.  
- The market was buoyed by China's central bank's commitment to support domestic demand, although concerns about industrial overcapacity and weak consumption dampened morning gains.  
- Hesai Group and SenseTime saw significant increases after being added to the MSCI China Index, while SMIC experienced a decline following fears of an AI-driven memory chip shortage.

Trading Economics

Hesai

Hang Seng Index

Hang Seng Trims Gains at Close

513700

Citi released a research report stating that WuXi Biologics is expected to significantly exceed market expectations for net profit in the second half of 2025, with revenue expected to grow by 17% year-on-year and net profit increasing by 38% to 2.6 billion RMB. Adjusted net profit is expected to rise by 31% to 3.7 billion RMB, with gross margin improving by 6.2 percentage points to 48.8%. The firm maintains WuXi Biologics as a preferred stock, with a target price of 48.5 RMB and a rating of "outperform."

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

In "The Big Banks," Citigroup: WuXi Biologics' net profit in the second half of the fiscal year far exceeds expectations, continuing to be the industry's top pick

WuXi BIO expects a 46% increase in net profit last year, exceeding RMB 4.9 billion, with a revenue growth of 16%. CHINA LIT issued a profit warning, expecting a full-year loss to widen to RMB 750 million to 850 million, mainly due to goodwill impairment. Leading Intelligent's new stock debut performed well, with a maximum gain of RMB 74. SMIC's profit grew by 60.66% last quarter, with sales revenue of USD 2.48 billion. ZEEKR released the world's first general-purpose warehouse robot Gino 1. Baoshan International's January revenue decreased by 32.5% year-on-year

Tasty Money

CHINA LIT

Bosera Hang Seng Health Care ETF(QDII)

[Daily Announcement] WUXI BIO (2269) expects a 46% increase in net profit last year, CHINA LIT (772) issues a profit warning, expecting an expanded annual loss

WuXi Biologics (Cayman) Inc shares rose 4.1% to HK$41.68, reaching a four-month high. The company anticipates a 46.3% increase in 2025 profit to 4.91 billion yuan ($710.21 million) and a 16.7% rise in revenue to 21.79 billion yuan. The gross profit margin is expected to improve by 5 percentage points to 46%. This growth is attributed to expanded services, increased research revenue, and efficiency improvements. Year-to-date, the stock is up 29.9%, outperforming the Hang Seng Biotech Index, which is up 13.3%.

CAM HSBIOTECH

WuXi Biologics climbs to 4-month high on robust earnings estimates

The Hang Seng Index opened 63 points higher, reporting at 27,246 points. WUXI BIO expects a 46.3% increase in net profit last year, with its stock price opening 3.54% higher; SMIC reported a net profit of USD 173 million in the fourth quarter of last year, with its stock price opening 2.3% lower. In the U.S. stock market, the Dow Jones rose slightly, while the S&P 500 and Nasdaq fell. Tech stocks showed mixed performance, with Tencent down over 1% and Alibaba slightly up. Southbound funds net bought HKD 84.8 million in Hong Kong stocks

- U.S. stocks showed mixed results, with the Dow Jones reaching a record high of 50,512 points, closing up 52 points or 0.1%.  
- The S&P 500 fell 23 points or 0.33%, while the Nasdaq decreased by 135 points or 0.59%.  
- Major tech stocks like Tesla increased by 1.89%, whereas others like Alphabet and Amazon experienced declines.

Stheadline

SMIC

The Hang Seng Index opened 63 points higher, WUXI BIO rose 3.5% on positive earnings, and SMIC fell 2% | Hong Kong stock market opens

LABD

IBBQ

SBIO

WuXi Biologics (Cayman) Inc. expects its revenue for 2025 to rise by 16.7% to RMB21.79 billion, with a gross profit margin projected to increase by 5 percentage points to 46.0%. Adjusted gross profit is anticipated to reach approximately RMB10.64 billion, reflecting a year-on-year growth of 25.5%. The company credits this growth to the ramp-up of its European manufacturing facility, cost savings, efficiency improvements, and investment gains.

Direxion S&P Biotech Bear 3X

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

SPDR S&P Biotech

VG Health

iShares US Pharma

iShares Global Healthcare

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Health Care Select Sector SPDR

Wuxi Biologics Expects 2025 Revenue to Rise 16.7% to RMB21.79 Billion

WuXi Biologics (Cayman) :FY REVENUE RMB 21,790 MILLIONFY PROFIT EXPECTED TO INCREASE TO RMB5,733 MILLIONFY ADJUSTED NON-IFRS NET PROFIT EXPECTED TO INCREASE TO RMB6,586 MILLION

Wuxi Biologics FY Revenue RMB21,790 Million

The Hang Seng Index opened higher, refreshing its nearly four-year high; Tencent's performance exceeded expectations, receiving collective bullish calls from major banks; Chip stocks strengthened on the logic of domestic substitution, with SMIC leading the gains; Ping An's stake increase in China Taiping H-shares ignited the insurance sector; Cryptocurrency concept stocks surged as Bitcoin hit a new high; In the pharmaceutical sector, Jingtai Holdings reported its first profit, rising over 11%, while East Buy saw a sudden 12% increase.

Tencent

TENCENT

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Ping An Insurance

PING AN

PING AN-R

Ping An Ins HK SDR2to1

Ping An

SMIC HK SDR 5to1

CPIC

CHINA TAIPING

SUNSHINE INS

Life and Health Insurance

REMEGEN

RemeGen

BEONE MEDICINES

BeOne Medicines

Beigene

FI2 CSOP HSI

HUA HONG SEMI

Hua Hong

INNOCARE

InnoCare Pharma

GRANDSHORES

AKESO

HORIZONROBOT-W

ZA ONLINE

SINOHOPE TECH

GUOTAI JUNAN I

XTALPI

Life Sciences Tools and Services

XL2CSOPHSTECH

Semiconductors

FL2 CSOP HSI

LINEKONG

INNOVENT BIO

OKG TECH

Interactive Media and Services

CSOP HS TECH

XI2CSOPHSTECH

EAST BUY

Hot Trades in Hong Kong Stocks (8.14) | Hang Seng Index Hits Four-Year High at Opening, Morgan Stanley Says Foreign Capital Accelerated Inflows into Chinese Stock Market in July

Hong Kong stocks' innovative medicine sector surges 66%, three-pronged approach ignites the golden track

3SBIO

DUALITYBIO-B

HENGRUI PHARMA

Hengrui Pharma

Hong Kong stocks' innovative drugs surge 66%! Three major catalysts ignite the 'golden track', can we still get on board in the second half of the year?

HS#WUXI RC2608A(64343.HK)

"Big Banks" Bank of America Securities: WUXI BIO's earnings surprise is stable, raising target price to 47 yuan

"Hong Kong Stocks" Hang Seng Index fell 242 points in the half-day, with technology investment stocks leading the decline, while domestic property and WuXi AppTec stocks performed well

Nomura raises WUXI BIO's target price to 50.54 yuan, with preliminary annual performance exceeding expectations

"Hong Kong Stocks" The Hang Seng Index opened 55 points lower, Netease and Bud APAC declined, WUXI BIO rose

WuXi XDC Launches Cash Offer to Acquire All Remaining Shares of BioDlink